

November 25, 2014

The Dy. General Manager,
Dept. of Corporate Affairs,
The Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai: 400 001.

Dear Sir,

Sub: Result of Postal Ballot (including E-voting)

This is with reference to the Postal Ballot Notice filed with you in respect of proposal for seeking the approval of the public equity shareholders of the Company by Postal Ballot (including E-voting) as per Section 110 and other applicable provisions, if any of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 and Clause 35B of the Listing Agreement executed by the Company with the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited and in terms of the SEBI Circular Nos. CIR/CFD/DIL/5/2013 dated February 4, 2013 and CIR/CFD/DIL/8/2013 dated May 21, 2013. In terms of the said SEBI Circulars Postal Ballot/E-voting was provided only to the public equity shareholders (other than Promoter and Promoter group) of the Company.

Voting by postal ballot was sought to be initiated for seeking approval from the public equity shareholders pursuant to the provisions of Sections 391 to 394 of the Companies Act, 1956 or the applicable provisions of the Companies Act, 2013 to the proposed Scheme of Amalgamation of Glenmark Generics Limited and Glenmark Access Limited ("Transferor Companies") with Glenmark Pharmaceuticals Limited ("Transferee Company").

Further thereto, the Company has conducted a Postal Ballot (including E-voting) seeking approval of the public equity shareholders to the proposed Scheme.

The Board of Directors in compliance with Rule 22(5) of the Companies (Management and Administration) Rules, 2014 appointed Mr. Surjan Singh Rauthan of M/s. S. S. Rauthan & Associates, Practicing Company Secretary, as a Scrutinizer for conducting the said Postal Ballot/E-voting process in a fair and transparent manner. The Scrutinizer has submitted his report dated November 24, 2014 to the Chairman.

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026

CIN No: L24299MH1977PLC019982 E: complianceofficer@glenmarkpharma.com





On the basis of the report received from Scrutinizer, the Chairman today i.e., November 25, 2014 declared that the said Resolution has been approved as the votes cast by the public equity shareholders in favour of the proposal are more than the number of votes cast by the public equity shareholders against it.

Please find enclosed the details of combined voting results of the Postal ballot (including E-voting pursuant to Clause 35A and Clause 35B of the Listing Agreement).

The copy of the Scrutinizer's Report will be available on the Company's website www.glenmarkpharma.com

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Ltd.

Sanjay Kumar Chowdhary
Company Secretary & Compliance Officer

Encl: as above



Glenmark

A new way for a new world

Outcome of Voting of Postal Ballot/E-Voting (As per Clause 35A of Listing Agreement)

Date of General Meeting/Declaration Postal Ballot/E-Voting Results	Tuesday, November 25, 2014	
Total Number of Shareholders on Record Date (i.e. October 10, 2014 – cut-off date)	55,929	
No. of shareholders casted their votes through Postal Ballot/E-voting	Promoters & Promoter Group*	Public
	NA	858
No. of shareholders attended the meeting through video conferencing	Promoters & Promoter Group	Public
	N.A.	
Details of Agenda	Approval of the Scheme of Amalgamation of Glenmark Generics Limited and Glenmark Access Limited (“Transferor Companies”) with Glenmark Pharmaceuticals Limited (“Transferee Company”).	
Resolution required: (Ordinary/Special)	Consent pursuant to the provisions of Section 391 to 394 of the Companies Act, 1956 or the applicable provisions of the Companies Act, 2013 to the scheme of Amalgamation of Glenmark Generics Limited and Glenmark Access Limited with the Company i.e. Glenmark Pharmaceuticals Limited.	
Mode of Voting: (Show of hands/Poll/Postal Ballot/E-voting)	Postal Ballot/E-voting	

Given below is the resolution wise combined Result of Postal Ballot (including E-voting).

Category	No. of Shares Held [#] (1)	No. of Votes Polled [§] (2)	% of Votes Polled on outstanding shares (3) =[(2)/(1)]*100	No. of Votes - in favour (4)	No. of Votes - against (5)	% of Votes in favour on votes polled (6)= [(4)/(2)]*100	% of Votes against on votes polled (7)= [(5)/(2)]*100
Promoter and Promoter Group*	NA	NA	NA	NA	NA	NA	NA
Public – Institutional Holders	112,421,811	83,084,567	73.904	83,084,567	0.000	100.000	0.000
Public-Others	27,811,722	3,977,394	14.307	3,974,878	2,516	99.937	0.063
Total	140,233,533	87,061,961	62.083	87,059,445	2,516	99.997	0.003

[#] voting rights are in proportion to shares held as on October 10, 2014.

[§] excludes invalid votes.

*In terms of the SEBI Circular Nos. CIR/CFD/DIL/5/2013 dated February 4, 2013 and CIR/CFD/DIL/8/2013 dated May 21, 2013, Postal Ballot/E-voting was provided only to the public equity shareholders (other than Promoter and Promoter group) of the Company.

As per the results of Postal Ballot/E-voting on Resolution passed by the public equity shareholders is passed by requisite majority.

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026

CIN No: L24299MH1977PLC019982 E: complianceofficer@glenmarkpharma.com

